,
2 min read
Entering the Philippine pharmaceutical market requires a clear understanding of the Philippines drug registration process, documentation standards, and applicable approval pathways. A structured approach to the generic drug registration Philippines process helps companies ensure compliance, avoid delays, and achieve faster market access while meeting evolving FDA Philippines requirements.
Responsible Agency
- Food and Drug Administration (FDA) Philippines, specifically, the Center for Drug Regulation and Research (CDRR) is responsible for the entire Philippines drug registration process.
Main Steps in the Generic Drug Registration Process
| Step | Activity | Details |
|---|---|---|
| 1 | Obtain License to Operate (LTO) | Only companies with a valid FDA License to Operate may apply. |
| 2 | Prepare Dossier/Requirements | Use the ASEAN Common Technical Dossier (ACTD) format, as required by AO No. 2013-0021 and AO No. 2024-0013; checklist published on FDA website. Preparing a compliant ACTD dossier Philippines is critical for successful evaluation and approval. |
| 3 | Online Application | Submission is via the FDA eServices Portal (https://eservices.fda.gov.ph). You select “Drug” and classification (e.g., generic prescription). |
| 4 | Pre-assessment | FDA checks completion of documents; incomplete applications are not accepted. |
| 5 | Order of Payment | Issued after document completeness is confirmed. |
| 6 | Evaluation | Technical review of dossier—may include full, abridged, or verification/reliance pathway reviews. |
| 7 | Decision Issuance | If approved, Certificate of Product Registration (CPR) is issued. If rejected, a deficiency notice or disapproval is given. |
Documentary Requirements (for Initial Registration)
- Administrative data: Accomplished and notarized Integrated Application Form (in excel and pdf)
- Authorization letter (if applicable)
- Contract manufacturing agreement (if applicable)
- GMP certificates (manufacturer/contract manufacturer)
- Business registration: DTI/SEC/CDA for various ownership types
- ASEAN Common Technical Dossier:
- Part I: Administrative data and product info
- Part II: Quality documents
- Labeling materials
- Risk Management Plan: Generally not required for generic drugs unless requested
Fees
| Status | Application Fee (5 Years) | Brand Name Clearance | Annual Fee | Legal & Research Fee (LRF) |
|---|---|---|---|---|
| Unbranded | PHP 10,100 | – | PHP 2,000/year | 1% of application fee |
| Branded | PHP 15,150 | PHP 510/proposed brand name | PHP 3,000/year | 1% of application fee + PHP 30/brand |
Applicant may choose between 2-year or 5-year CPR validity.
Evaluation Timelines
| Review Type | Timeline (working days) |
|---|---|
| Preassessment | 5 (subject to completeness of documents) |
| Full Review | up to 120 (response time to deficiencies is excluded) |
| Abridged Review | 45 |
| Verification Review | 30 |
| Renewal | 20 |
Registration Pathways
- Standard Full Review: For most generics.
- Facilitated Pathways (Abridged, Verification): If product is already approved by a Reference Drug Regulatory Agency (e.g. US FDA, EMA).
- WHO Prequalified, ASEAN Joint Assessment: Special collaborative and reliance reviews where applicable.
Important Notes / Distinctions
- Separate applications are required for each API, pharmaceutical form, strength, and route of administration.
- Preassessment is mandatory—applications must be complete to proceed.
- Both innovator and generic drugs now use harmonized, streamlined processes; reliance/review on reference agencies’ approvals is increasingly favored for generics but not always applicable.
Table: Process Overview and Fees
| Step / Requirement | Unbranded Generic | Branded Generic | Agency Responsible | Timeframe (approx.) |
|---|---|---|---|---|
| License to Operate (prior to CPR) | Required | Required | FDA | – |
| Application (eServices Portal) | Yes | Yes | FDA/CDRR | n/a |
| Dossier (ACTD Format) | Yes | Yes | FDA | n/a |
| GMP Certificate(s) | Yes | Yes | FDA | n/a |
| Application Fee (5yr) + LRF | PHP 10,100+LRF | PHP 15,150+LRF | FDA | – |
| Brand Name Clearance | – | PHP 510/ proposed brand name | FDA | – |
| Evaluation (Standard) | Yes | Yes | FDA (CDRR) | Up to 120 days (excludes deficiency compliance and other related correspondences) |
| Abridged/Verification Pathway (for eligible) | Yes | Yes | FDA (CDRR) | 30–45 days |
| Renewal (before expiry of CPR) | Yes | Yes | FDA | Filing of renewal is still allowed within 90 days before expiry, renewals filed within 120 days from expiry remain valid but will incur surcharge
|
Conclusion
Successfully navigating the generic drug registration Philippines pathway requires accurate documentation, compliance with FDA Philippines requirements, and timely responses to Regulatory queries.
Freyr supports pharmaceutical companies with end-to-end expertise across the Philippines drug registration process ensuring faster approvals and seamless market entry.
